11.55
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$11.65
Aprire:
$11.45
Volume 24 ore:
403.40K
Relative Volume:
0.52
Capitalizzazione di mercato:
$620.22M
Reddito:
$8.78M
Utile/perdita netta:
$-104.70M
Rapporto P/E:
-4.8734
EPS:
-2.37
Flusso di cassa netto:
$-82.68M
1 W Prestazione:
-2.20%
1M Prestazione:
+16.55%
6M Prestazione:
+2.48%
1 anno Prestazione:
-9.98%
Stoke Therapeutics Inc Stock (STOK) Company Profile
Nome
Stoke Therapeutics Inc
Settore
Industria
Telefono
781-430-8200
Indirizzo
45 WIGGINS AVENUE, BEDFORD, MA
Confronta STOK con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
STOK
Stoke Therapeutics Inc
|
11.55 | 620.22M | 8.78M | -104.70M | -82.68M | -2.37 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
2024-10-14 | Ripresa | Leerink Partners | Outperform |
2024-03-26 | Aggiornamento | TD Cowen | Market Perform → Outperform |
2023-11-20 | Ripresa | JP Morgan | Neutral |
2023-07-25 | Downgrade | TD Cowen | Outperform → Market Perform |
2023-05-01 | Aggiornamento | BofA Securities | Underperform → Neutral |
2023-04-26 | Ripresa | Canaccord Genuity | Buy |
2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
2022-10-24 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
2022-01-31 | Iniziato | Jefferies | Buy |
2021-12-03 | Iniziato | BofA Securities | Buy |
2021-11-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
2021-05-18 | Iniziato | UBS | Neutral |
2021-05-10 | Aggiornamento | Wedbush | Neutral → Outperform |
2021-04-26 | Ripresa | Credit Suisse | Outperform |
2021-02-10 | Downgrade | Wedbush | Outperform → Neutral |
2020-12-15 | Ripresa | H.C. Wainwright | Buy |
2020-12-11 | Reiterato | Needham | Buy |
2020-10-23 | Iniziato | Cantor Fitzgerald | Overweight |
2020-09-29 | Ripresa | JP Morgan | Neutral |
2020-09-29 | Iniziato | Needham | Buy |
2019-12-18 | Iniziato | Wedbush | Outperform |
2019-11-12 | Iniziato | BTIG Research | Buy |
2019-10-25 | Iniziato | H.C. Wainwright | Buy |
2019-07-15 | Iniziato | Canaccord Genuity | Buy |
2019-07-15 | Iniziato | Cowen | Outperform |
2019-07-15 | Iniziato | Credit Suisse | Outperform |
2019-07-15 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Stoke Therapeutics Inc Borsa (STOK) Ultime notizie
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | STOK Stock News - GuruFocus
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
STOK FY2025 EPS Forecast Lowered by Cantor Fitzgerald - Defense World
Stoke Therapeutics: Impressive Pipeline And Big Backers - Seeking Alpha
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Acquired by California State Teachers Retirement System - Defense World
FMR LLC Increases Stake in Stoke Therapeutics Inc: A Strategic M - GuruFocus
Cantor Fitzgerald Comments on STOK FY2026 Earnings - Defense World
Encephalopathy Pipeline 2025: Comprehensive Clinical Trials - openPR.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Sold by Two Sigma Investments LP - Defense World
Ameriprise Financial Inc. Has $116,000 Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Jane Street Group LLC Sells 318,465 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - mx.advfn.com
Millennium Management LLC Increases Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
(STOK) Technical Data - news.stocktradersdaily.com
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Insider Sell: Barry Ticho Sells 8,216 Shares of Stoke Therapeuti - GuruFocus
Insider Sell: Barry Ticho Sells 8,216 Shares of Stoke Therapeutics Inc (STOK) - GuruFocus
Stoke Therapeutics Adopts Key Proposals at Annual Meeting - TipRanks
BNP Paribas Financial Markets Trims Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
ProShare Advisors LLC Acquires Shares of 12,626 Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Contrasting Stoke Therapeutics (NASDAQ:STOK) & Renovaro (NASDAQ:RENB) - Defense World
Stoke Therapeutics to Present at the 2025 Jefferies Global Healthcare Conference - BioSpace
Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference | STOK Stock News - GuruFocus
Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference - Business Wire
D. E. Shaw & Co. Inc. Sells 143,203 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
How to Take Advantage of moves in (STOK) - news.stocktradersdaily.com
Northern Trust Corp Purchases 11,635 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 28% But Its Business Still Trails The Industry - simplywall.st
Chardan Capital Has Strong Forecast for STOK FY2025 Earnings - Defense World
Analysts Issue Forecasts for STOK FY2026 Earnings - Defense World
Research Analysts Issue Forecasts for STOK FY2025 Earnings - Defense World
Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet - MSN
HC Wainwright Analysts Decrease Earnings Estimates for STOK - Defense World
Q2 EPS Estimates for Stoke Therapeutics Raised by Wedbush - Defense World
Stoke Therapeutics (NASDAQ:STOK) Stock Rating Upgraded by Cantor Fitzgerald - Defense World
Stoke Therapeutics stock target cut to $35 by H.C. Wainwright - Investing.com Canada
Price T Rowe Associates Inc. MD Purchases 2,215 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
STOK: HC Wainwright & Co. Maintains Buy Rating on Stoke Therapeu - GuruFocus
Stoke Therapeutics (STOK) Sees Adjusted Price Target Amid Upcoming Trial | STOK Stock News - GuruFocus
Stoke Therapeutics (STOK) Sees Adjusted Price Target Amid Upcomi - GuruFocus
Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up After Better-Than-Expected Earnings - Defense World
Stoke Therapeutics Advances with Strong Q1 2025 Results - TipRanks
Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates | STOK Stock News - GuruFocus
Stoke Therapeutics (STOK) Reports Significant Q1 Revenue Growth - GuruFocus
Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
Stoke Therapeutics Provides Business Updates - citybiz
Stoke Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Stoke Therapeutics Inc (STOK) Reports Q1 2025 Earnings: EPS of $ - GuruFocus
Stoke Therapeutics Q1 Operating Income USD 111.24 Million - marketscreener.com
Stoke Therapeutics Inc (STOK) Reports Q1 2025 Earnings: EPS of $1.90 and Revenue of $158.6 Million, Surpassing Estimates - GuruFocus
Stoke Therapeutics Inc Azioni (STOK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Stoke Therapeutics Inc Azioni (STOK) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Ticho Barry | CHIEF MEDICAL OFFICER |
Jun 03 '25 |
Sale |
10.03 |
6,471 |
64,892 |
25,782 |
Ticho Barry | CHIEF MEDICAL OFFICER |
Jun 02 '25 |
Sale |
10.00 |
1,745 |
17,450 |
32,253 |
Ticho Barry | CHIEF MEDICAL OFFICER |
May 02 '25 |
Sale |
10.03 |
22,790 |
228,543 |
33,998 |
Ticho Barry | CHIEF MEDICAL OFFICER |
May 01 '25 |
Sale |
10.00 |
3,841 |
38,410 |
56,788 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):